OpenAI CEO Sam Altman Plans ‘Fundamentally New Type of Computer' That Will Make AI ‘Transcendentally Good'
The conversation highlighted OpenAI's intent to move past existing voice assistants, with OpenAI COO Brad Lightcap explaining, 'You can build something that's really bad that [looks at your email and responds] today, but to get to the version of that that's transcendentally good, there's a ton of context and a ton of awareness that you have to have of like what each situational thing is that helps you craft exactly the right response.' Lightcap continued, 'Imagine that now in kind of any arbitrary situation and wanting to have that with you all the time. And so I think that's a very compelling direction for this type of hardware.'
Meta Platforms Stock Looks Cheap - Short OTM Puts for a 2% One-Month Yield
Is SoundHound AI Stock a Buy, Sell, or Hold for July 2025?
Can Circle Stock Hit $250 in 2025?
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
This approach underscores OpenAI's focus on contextually rich, situationally aware AI — an area where Altman's leadership has proven transformative. Altman, who co-founded OpenAI in 2015 alongside prominent technologists including Elon Musk, has consistently championed the responsible and beneficial deployment of artificial intelligence. His background as a serial entrepreneur, former president of Y Combinator, and investor in multiple technology startups has positioned him as a key architect of today's AI landscape.
When asked whether OpenAI's hardware would resemble existing products like Amazon's (AMZN) Alexa, Altman replied, 'Don't you just want to wait and be surprised and get some joy? It's been a long time since the world has gotten a fundamentally new kind of computer. Like, let us try.'
Altman's statement reflects his belief in the power of technological surprise and innovation. Under his leadership, OpenAI has introduced breakthrough products such as GPT-3, DALL-E, and ChatGPT, each pushing the boundaries of what AI can achieve and rapidly gaining millions of users worldwide. These achievements have not only demonstrated OpenAI's technical prowess but have also sparked global conversations about the future of human-computer interaction.
The push for 'a fundamentally new kind of computer' comes at a time when the market is saturated with incremental updates to existing devices, and consumers are increasingly seeking more intuitive, helpful, and context-aware technology. Altman's vision is informed by OpenAI's mission to develop artificial general intelligence that benefits humanity, a principle that has guided the company's strategy through both technical and ethical challenges.
Given Altman's track record — navigating OpenAI through funding challenges, boardroom controversies, and the rapid scaling of AI technologies — his authority in the field is well-established. He is frequently compared to other tech visionaries and has testified before governments on the societal implications of AI. As OpenAI explores new hardware in collaboration with figures like designer Jony Ive, Altman's pursuit of a 'transcendentally good' AI experience signals a new chapter for both the company and the technology sector at large.
On the date of publication, Caleb Naysmith did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
7 Kid Items To Stock Up on Before Tariff-Induced Shortages
If you've been following the news in recent months, you've probably heard a lot about higher tariffs being imposed on imported goods — especially those from Mexico, China and Canada. As a parent, you may also be wondering which kids items to stock up on before the stores run out. We're a Family of 5 Living on One Salary: Check Out: While you should only ever buy what you need, some experts believe it might be wise to make some purchases now — just in case those items disappear or skyrocket in price. Many kids toys (approximately 85% of those sold in the U.S., according to the Toy Association) are manufactured in China — one of the countries that'd be hit hardest by rising tariffs. Aaron Razon, personal finance expert at Couponsnake, said toys made in China are most likely to be in short supply due to proposed tariffs. This includes things like action figures, LEGO sets and Barbie dolls. These toys could also become more expensive — if you're even likely to find them on the shelves. Explore More: There could be a scarcity in kids' clothes, too, especially with back-to-school shopping. Razon said that coats, boots and other seasonal accessories could be harder to find. The same could be said for accessories like socks and underwear. But don't stock up out of fear. Only buy the things you already need for your kids. If consumers start to panic buy, retailers could potentially increase their prices accordingly. Some, especially online retailers, might also place limits on how much shoppers can purchase. Along those same lines, consider buying footwear — like athletic shoes or sandals — for your kids. Just don't go overboard with it. 'I think stocking up on these items could backfire on parents if everyone starts buying in bulk in anticipation of a shortage,' said Razon. 'I mean, apart from the fact that this could lead to a surge in demand, and potentially exacerbate the very shortage they are trying to prepare for, there is also the fact that it could lead to wasted resources.' Are you in the market for a new gaming console for your kids? You might only need the one console, but now could be a good time to buy. 'Tariffs affect kids and youth particularly hard since most toys, electronics and clothing are manufactured overseas, including gaming consoles,' said Liam Hunt, Director of Research at That's because many of these items are made in China and Southeast Asia. Gaming consoles aren't the only thing to consider buying. A lot of tech and accessories imported from abroad could become more expensive or see limited stock. Hunt suggested shopping early if you're looking for holiday gifts since prices will likely increase. Supply also tends to drop around these busier times. Tariffs have a trickle-down effect on both prices and availability. Things like bikes, scooters and backyard playground equipment could be in short supply due to tariffs. So, if you're in the market for any of these things, now might be the time to buy. 'It would be wise for parents to stock up on big-ticket items,' said Hunt. 'But avoid hoarding everyday items.' Do you have a little one on the way? Or are you already a proud parent (or grandparent, or aunt or uncle)? If so, you might want to grab essential baby gear like strollers or high chairs now. Razon said the availability of these items could also be impacted by tariffs. More From GOBankingRates These Cars May Seem Expensive, but They Rarely Need Repairs This article originally appeared on 7 Kid Items To Stock Up on Before Tariff-Induced Shortages
Yahoo
15 minutes ago
- Yahoo
Abbott Laboratories (NYSE:ABT) shareholders have earned a 9.6% CAGR over the last five years
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. Unfortunately for shareholders, while the Abbott Laboratories (NYSE:ABT) share price is up 44% in the last five years, that's less than the market return. However, more recent buyers should be happy with the increase of 29% over the last year. Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. Over half a decade, Abbott Laboratories managed to grow its earnings per share at 31% a year. This EPS growth is higher than the 8% average annual increase in the share price. Therefore, it seems the market has become relatively pessimistic about the company. You can see below how EPS has changed over time (discover the exact values by clicking on the image). We know that Abbott Laboratories has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Abbott Laboratories will grow revenue in the future. It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for Abbott Laboratories the TSR over the last 5 years was 58%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! It's good to see that Abbott Laboratories has rewarded shareholders with a total shareholder return of 32% in the last twelve months. That's including the dividend. That's better than the annualised return of 10% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Abbott Laboratories you should be aware of. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
15 minutes ago
- Associated Press
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. ('PepGen' or the 'Company') (NASDAQ: PEPG) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ('FDA') approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times. On July 30, 2024, PepGen issued a press release announcing purported 'positive clinical data from the first dose cohort (5 mg/kg) of PGN-EDO51' in its ongoing CONNECT1 study. Among other results, the Company reported that 'PGN-EDO51 achieved a mean absolute dystrophin level of 0.61% of normal and a 0.26% change from baseline after 4 doses, measured at week 13 by Western blot analysis.' However, as subsequently noted by a Stifel analyst, 'the magnitude of dystrophin increase was below what [PepGen] anticipated, which is disappointing[.]' Likewise, a Leerink Partners analyst noted that the low dose missed PepGen's expectations of 1% or greater dystrophin expression. On this news, PepGen's stock price fell $5.55 per share, or 32.69%, to close at $11.43 per share on July 31, 2024. On December 16, 2024, PepGen issued a press release announcing that it had received a clinical hold notice from the FDA regarding an Investigational New Drug ('IND') application 'to initiate the [CONNECT2] clinical trial in patients with [DMD]' in the U.S. Notably, the FDA's issuance of a clinical hold notice for the IND application indicated that the FDA had concerns regarding risks posed to patients in the CONNECT2 study and/or there were other deficiencies associated with the study. On this news, PepGen's stock price fell $0.17 per share, or 3.63%, to close at $4.51 per share on December 16, 2024. On January 29, 2025, PepGen issued a press release providing updates regarding safety concerns observed in the CONNECT1 study and the FDA's concerns regarding the CONNECT2 study. With respect to the CONNECT1 study, the press release stated, inter alia, that '[d]osing of one of the[] . . . participants [in the 10 mg/kg cohort] was paused due to a reduction of his estimated glomerular filtration rate[.]' In addition, PepGen 'ha[d] received communication from Health Canada . . . request[ing] additional information from the Company to address Health Canada's safety concerns before any further dose escalation or enrollment of any additional participants at the current dose levels.' With respect to the CONNECT2 study, the same press release stated, in relevant part, that '[t]he Company is working with the FDA to address its questions regarding supportive data for the dosing levels planned for the patient population.' Following these disclosures, PepGen's stock price fell $0.40 per share, or 21.74%, to close at $1.44 per share on January 30, 2025. On March 4, 2025, PepGen issued a press release 'announc[ing] its voluntary decision to temporarily pause the [CONNECT2] study . . . until the Company can review results from the 10 mg/kg cohort in the ongoing [CONNECT1] study.' On this news, PepGen's stock price fell $0.53 per share, or 18.86%, to close at $2.28 per share on March 4, 2025. Then, on May 28, 2025, PepGen issued a press release announcing that 'PGN-EDO51 did not achieve target dystrophin levels' in the CONNECT1 study and had chosen to discontinue development of its DMD programs. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding PepGen's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the PepGen class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at
